Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast Track designation for a third/fourth line treatment indication in NSCLC by the US Food & Drug Administration. In addition, the LUME-Lung Phase III clinical trial program, which is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC, is ongoing. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the early stages of clinical development.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on re
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Caliper Life ... provider of tools and services for drug discovery ... has completed the sale of Xenogen Biosciences Corporation ... services, to Taconic Farms, Inc. for approximately $11 ... part of Caliper,s acquisition of Xenogen Corporation in ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
(Date:12/14/2009)... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) ... directors with the addition of Lt. Gen. Ronald R. ... of Martin, Blanck & Associates, a federal health services ... addition, the company board now has nine members. ,, ... a medical officer and battalion surgeon in Vietnam. He ...
Breaking Medicine Technology:Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Health Experts Praise Intellicig Electronic Cigarette 54824 1Health Experts Praise Intellicig Electronic Cigarette 54824 2Health Experts Praise Intellicig Electronic Cigarette 54824 3Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 1Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 2Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 3Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 4Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 5Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 6Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 7Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 8Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 9Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 10Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 11Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 12Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 13Sinovac Reports Unaudited Second Quarter 2009 Financial Results 54820 14Iterative reconstruction technique significantly reduces patient radiation dose during CT scans 54816 1
... U.S., U.K. and China TrialsSAN DIEGO, Jan. 7 ... liver disease, today announced patient enrollment has begun for ... will study the Extracorporeal Liver Assist Device (ELAD) as ... under three protocols. The study is open for enrollment ...
... NEW YORK, Jan. 6 The Michael J. Fox ... four industry research teams for pre-clinical research on potential ... the Foundation,s Therapeutics Development Initiative. This program, ... on Parkinson,s research. TDI is part of ...
Other Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2
(Date:12/14/2009)... 14 Pepsi Bottling Group, ArvinMeritor, Inc., ... are among the major employers that implemented Thomson ... their employees make better decisions about their benefits. ... personalized summary of their families, use of healthcare ... this personalized information, employees can determine which of ...
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... To Wear Pink(TM) (TETWP), the grassroots cowboy campaign ... at the signature Tough Enough To Wear Pink ... NFR) in Las Vegas. While pink is not ... of the western industry and rodeo fans was ... hats, bracelets and more. ,, Through the ...
(Date:12/14/2009)... up 900-Member Physician Staff , ... La Jolla, Calif. ... elected Marc Sedwitz, MD, as the new chief of staff of ... the 900-member physician team on Jan. 1, 2010. , , , ... staff liaison to Scripps La Jolla’s administrative staff and its board ...
(Date:12/14/2009)... Tens of Thousands of New Chronic Hepatitis Infections ... Legislation approved by Congress providing for federal funding ... to reduce tens of thousands of new viral ... States, the National Viral Hepatitis Roundtable ... in the FY 2010 Consolidated Appropriations bill approved ...
Breaking Medicine News(10 mins):Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2
... IRVINE, Calif., Jan. 19 PatientFYI,( http://www.patientfyi.com ), ... way patients select doctors, debuted this week with ... dentists,including over 50,000 with enhanced Practice Profiles. , ... improved the way sellers present their,strengths, and buyers ...
... Awards)PHILADELPHIA, Jan. 19 GlaxoSmithKline, one of the ... announced the recipients of the GlaxoSmithKline 12th Annual ... services. Each Pennsylvania-based nonprofit will receive a $40,000 ... Tuesday, March 17 at GlaxoSmithKline in Philadelphia where ...
... WASHINGTON, Jan. 19 The U.S. bishops urged ... that protect conscience rights of health care workers, ... ban funding of stem cell research that encourages ... a January 16 letter from Cardinal Francis George, ...
... Center for Health Innovation Discusses the Impact of the Economic ... A new report released today ... advisory firm to health providers, has found that hospitals and ... both capital spending and unprofitable healthcare services as a result ...
... bank, experts say , , MONDAY, Jan. 19 (HealthDay News) ... but you don,t have to shortchange your health. , Experts ... live healthy and cut their risk of cancer without breaking ... , Get moving . Moderate to intensive aerobic exercise, ...
... Jan. 19 Back in 2000 Katie Couric told Americans ... -- but only if you get tested in time . ... that according to the National Cancer Institute (NCI), as recently ... certain whether colonoscopy can help reduce the number of deaths ...
Other Medicine News:Health News:PatientFYI is Revolutionizing the Way Patients Find the Best Doctors to Serve Their Needs 2Health News:PatientFYI is Revolutionizing the Way Patients Find the Best Doctors to Serve Their Needs 3Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 2Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 3Health News:GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding 4Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 2Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 3Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 4Health News:Bishops Urge New President to Keep Laws on Conscience Rights, Foreign Aid for Abortion, Embryonic Stem Cell Research 5Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 3Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 4Health News:Low-Cost Strategies to Maintain Health in Hard Times 2Health News:Katie Couric Misrepresented Screening Benefits - Claims 'Death By Colonoscopy' Expose 2
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
...
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
Medicine Products: